Respiratory syncytial virus-related pneumonia after stem cell transplantation successfully treated with palivizumab and steroid therapy

Scand J Infect Dis. 2004;36(2):155-7. doi: 10.1080/00365540410019282.

Abstract

A case is reported of a 56-y-old woman with a second relapse of Hodgkin's disease who early developed after autologous stem cell transplantation (ASCT) a severe RSV-related interstitial pneumonia successfully treated with 1-d intravenous palivizumab 8 mg/kg plus low-dose systemic steroid therapy. B-cells suppression with CMV antigenaemia were then observed and required treatment with ganciclovir and liposomal amfotericine B.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Hodgkin Disease / diagnosis
  • Hodgkin Disease / therapy
  • Humans
  • Infusions, Intravenous
  • Middle Aged
  • Palivizumab
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / virology
  • Recurrence
  • Respiratory Syncytial Virus Infections / diagnosis
  • Respiratory Syncytial Virus Infections / drug therapy*
  • Respiratory Syncytial Virus Infections / etiology*
  • Severity of Illness Index
  • Stem Cell Transplantation / adverse effects*
  • Stem Cell Transplantation / methods
  • Steroids / administration & dosage*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Steroids
  • Palivizumab